 Daphnectin has shown promising anti-cancer properties in both in vitro and in vivo studies. It has demonstrated strong anti-proliferative activity against several cancer cell lines with the most potent activity observed against B16 melanoma cells. Furthermore, it has also exhibited significant anti-tumor activity in animal models of various cancers, including B16 melanoma, MXD breast adenocarcinoma, C26 colon carcinoma, and S180 fibrosarcoma. These findings suggest that Daphnectin may be a promising candidate for further development as an effective anti-cancer drug. This article was authored by F. Alejandro Jimenez Orozco, Ivan Randolovic, Zeta Haggadis, and others.